🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Meningioma

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site📍 Boadilla del Monte Fundación de investigación HM · Tests: Olaparib; 177Lu-DOTATATE 3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features NCT06955208NA1 site📍 Shenyang Shengjing Hospital · Tests: Magnetic Resonance Elastography, Intraoperative Assessment and Recording RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma NCT07150806Phase 1, Phase 21 site📍 Columbus Joshua Palmer · Tests: Actinium Ac 225 DOTATATE RYZ101, Biospecimen Collection, Computed Tomography, Echocardiography Test, Gallium Ga 68-DOTA… Natural History Study of Patients With Neurofibromatosis Type 2 NCT00598351n/a1 site📍 Bethesda National Institute of Neurological Disorders and Stroke (NI… Evaluation of the CONVIVO System NCT05139277NA1 site📍 Lebanon Dartmouth-Hitchcock Medical Center · Tests: CONVIVO system, Conventional histologic evaluation 177Lu-DOTATATE for Recurrent Meningioma NCT06326190Phase 219 sites📍 Innsbruck📍 Vienna📍 Lyon European Organisation for Research and Treatment of Cancer … · Tests: Local standard of Care, 177Lu-DOTATATE Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults NCT04501705NA1 site📍 Beijing Beijing Sanbo Brain Hospital · Tests: Apatinib Mesylate Regorafenib for Recurrent Meningioma (MIRAGE Trial) NCT06275919Phase 220 sites📍 Meldola📍 Messina📍 Bagno a Ripoli Istituto Oncologico Veneto IRCCS · Tests: Regorafenib 40 MG Oral Tablet, Local Standard of Care Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment NCT06955169Phase 217 sites📍 Irvine📍 La Jolla📍 New Haven RTOG Foundation, Inc. · Tests: [177Lu]Lu-DOTATATE, Standard of Care treatments Robot-Assisted Neurovascular Intervention NCT06752096NA1 site📍 Seoul Navigantis Inc. · Tests: cerebral angiography, arterial embolization, thrombectomy, Cerebral angiogram using robotic device, Meningioma emboliza… HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer) NCT06930846NA1 site📍 Lebanon Dartmouth-Hitchcock Medical Center · Tests: HOBSCOTCH-CA Abemaciclib in Newly Diagnosed Meningioma Patients NCT05940493Phase 21 site📍 Phoenix Nader Sanai · Tests: Abemaciclib, Placebo Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE NCT06377371Phase 41 site📍 New York Weill Medical College of Cornell University · Tests: Brain Imaging with [Cu64]DOTATATE, Radio-guided Surgery With Neoprobe Utilization Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) NCT04427384n/a54 sites📍 Phoenix📍 Little Rock📍 Castro Valley GT Medical Technologies, Inc. · Tests: GammaTile Predictive Factors for Survival in Aggressive Meningiomas NCT05793034NA1 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: Biological biomarker assessment Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial NCT06126588Phase 22 sites📍 Vandœuvre-lès-Nancy📍 Vandœuvre-lès-Nancy Central Hospital, Nancy, France · Tests: Everolimus Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema NCT06710249Phase 21 site📍 Lund Peter Siesjö · Tests: Salovum/SPC flakes UCSD Image-Guided Cognitive-Sparing Radiosurgery for Intracranial Lesions NCT04343157Phase 21 site📍 San Diego Jona Hattangadi-Gluth · Tests: Cognitive Sparing Brain Stereotactic Radiosurgery (SRS) Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas: Proof-of-concept Study NCT07398170NA1 site📍 Montpellier University Hospital, Montpellier · Tests: Blood sampling, Lumbar puncture Intraoperative Brain Shift Calculation Study NCT05477680NA1 site📍 Moscow Sklifosovsky Institute of Emergency Care · Tests: Navigation-guided surgery Multicenter Trial on Surgical Outcome and Quality of Life in Juxta-medullary Tumors NCT07056023n/a1 site📍 Münster University Hospital Muenster Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With Meningiomas NCT07044076n/a1 site📍 Paris Centre Hospitalier St Anne · Tests: Quality of life Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome NCT04792463n/a1 site📍 Columbus Mohamed Abdel-Rahman SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON) NCT05254197n/a1 site📍 Seoul Seoul National University Hospital Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial NCT06132685Phase 21 site📍 Atlanta Emory University · Tests: Biospecimen Collection, Computed Tomography, Dexamethasone, Magnetic Resonance Imaging, Questionnaire Administration Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide NCT04997317Phase 1, Phase 21 site📍 Basel University Hospital, Basel, Switzerland · Tests: 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over), 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over),… IN10018 in Combination With Dalpiciclib for Progressive Meningiomas NCT07652762Phase 12 sites📍 Beijing📍 Beijing Capital Medical University · Tests: Ifebemtinib, Dalpiciclib SIMPLIFication of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence NCT06878469NA2 sites📍 Milan📍 L’Aquila Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Tests: RehaCom Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) NCT04374305Phase 26 sites📍 Los Angeles📍 Miami📍 Indianopolis Scott R. Plotkin, MD, PhD · Tests: Brigatinib, Neratinib, Retifanlimab, Bevacizumab A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma NCT07428616Phase 220 sites📍 Birmingham📍 Phoenix📍 San Francisco Exelixis · Tests: Zanzalintinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy